This Study Opens Door for Exploring New Antidepressants Therapy

By on
This Study Opens Door for Exploring New Antidepressants Therapy Through Inhibiting Jnk
PHOTOGRAPH: Jarmoluk/Pixabay |

The JNK, a certain kind of protein, when inhibited is found to alleviate a person’s mood responses. This discovery opens up new avenues for antidepressants to be explored for many patients’ treatment, especially for those who are resistant.

Researchers from the Abo Akademi University in Finland were able to discover a new therapy approach that involves tapping into the brain’s neurogenesis, the growth of new nerve cells in the brain. Coupled with the inhibition of c-Jun N-terminal kinases (JNK), the Finnish scientists led by Eleanor Coffey saw a remarkable finding.

A Positive Mood Response

The JNK was seen to moderate neurogenesis in the brain’s hippocampus, the area of our brain that controls learning and emotions. When the mice in the study, published in journal Molecular Psychiatry, was inhibited with JNK, its anxiety levels were observed to lessen while neurogenesis increased.

Through their virus tools, the researchers were able to see the area in the brain that improved the one’s mood. The findings show the combination of JNK and new cell growth relieves mood disorders with a powerful neurogenic stimulus. This mechanism sheds light into understanding the disorder more through knowing how the brain works in regulating one’s moods, which in turn, paves way for exploring its therapies.

Finding Medication For Treatment-Resistant Patients

Throughout the years, treatments for anxiety and depression made much-needed huge leaps. Considering how millions of people, around 350 million to be exact according to the World Health Organization, are suffering from depression, further research is undoubtedly critical.

Moreover, there are many patients who do not respond to the treatments we have today. That is why the finding of the study is highly significant since learning the disorder’s mechanism is essential in infiltrating drugs for treatment-resistant patients.

The JNK has been involved in many disease studies in fields such as metabolic, neurodegenerative, inflammatory, oncological and vascular. With mood disorders added to the roster, what is next to watch out for is how the JNK protein-inhibited antidepressants would work in humans.


About the author

To Top